Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment

Analytical and Bioanalytical Chemistry

Volumn 405, Issue 6, 2013, Pages 1903-1911

  Chen, Baowei ^a   Cao, Fenglin ^b   Yuan, Chungang ^c   Lu, Xiufen ^a   Shen, Shengwen ^a   Zhou, Jin ^b   Le, X Chris ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c NORTH CHINA ELECTRIC POWER UNIVERSITY   (China)

Author keywords

Acute promyelocytic leukemia; Arsenic speciation; Arsenic trioxide treatment; Metabolism; Saliva

Indexed keywords

ALKYLATION; DISEASES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLITES;

ARSENIC SPECIATION; ARSENIC TRIOXIDE; CLINICAL BIOMARKERS; DIMETHYLARSINIC ACIDS; MONOMETHYLARSONIC ACIDS; MONOMETHYLARSONOUS ACIDS; PROMYELOCYTIC LEUKEMIA; SALIVA;

PATIENT TREATMENT;

EID: 84873708718     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-6700-5     Document Type: Article

References (52)

1. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89(9):3354-3360
2. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10):3315-3324
3. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H (2002) How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2(9):705-713
4. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107(7):2627-2632
5. Quezada G, Kopp L, Estey E, Wells RJ (2008) All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Pediatr Blood Cancer 51(1):133-135
6. Leu L, Mohassel L (2009) Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Am J Health Syst Pharm 66(21):1913-1918
7. Wang H, Hao L, Wang X, Li J, Wu Q, Bian S (2010) Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience. Int J Hematol 91(5):820-825
8. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF (2001) Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98(2):266-271
9. Cashin R, Burry L, Peckham K, Reynolds S, Seki JT (2008) Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia. Am J Health Syst Pharm 65(10):941-946
10. 3 exerts dose-dependent dual effects on APL cells. Blood 89(9):3345-3353
11. Zhu Q, Zhang JW, Zhu HQ, Shen YL, Flexor M, Jia PM, Yu Y, Cai X, Waxman S, Lanotte M, Chen SJ, Chen Z, Tong JH (2002) Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 99(3):1014-1022
12. Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, Chen Z, Waxman S (2003) Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 63(8):1853-1859
13. Li L, Wang J, Ye RD, Shi G, Jin H, Tang X, Yi J (2008) PML/RARα fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase. J Cell Physiol 217(2):486-493
14. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de The H, Chen SJ, Chen Z (2010) Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science 328(5975):240-243
15. Wang Z, Zhou J, Lu X, Gong Z, Le XC (2004) Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 17(1):95-103
16. Fukai Y, Hirata M, Ueno M, Ichikawa N, Kobayashi H, Saitoh H, Sakurai T, Kinoshita K, Kaise T, Ohta S (2006) Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Biol Pharm Bull 29(5):1022-1027
17. Yoshino Y, Yuan B, Miyashita S, Iriyama N, Horikoshi A, Shikino O, Toyoda H, Kaise T (2009) Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem 393(2):689-697
18. Thomas DJ, Waters SB, Styblo M (2004) Elucidating the pathway for arsenic methylation. Toxicol Appl Pharmacol 198(3):319-326
19. Bentley R, Chasteen TG (2002) Microbial methylation of metalloids: arsenic, antimony, and bismuth. Microbiol Mol Biol Rev 66(2):250-271
20. Cullen WR, Reimer KJ (1989) Arsenic speciation in the environment. Chem Rev 89:713-764
21. Le XC (2001) Arsenic speciation in the environment and humans. In: Frankenberger WT Jr (ed) Environmental chemistry of arsenic. Dekker, New York, pp 95-116
22. Sun G, Xu Y, Li X, Jin Y, Li B, Sun X (2007) Urinary arsenic metabolites in children and adults exposed to arsenic in drinking water in Inner Mongolia, China. Environ Health Perspect 115(4):648-652
23. Yuan C, Lu X, Oro N, Wang Z, Xia Y, Wade TJ, Mumford J, Le XC (2008) Arsenic speciation analysis in human saliva. Clin Chem 54(1):163-171
24. Lew K, Yuan CG, Acker JP, Le XC (2008) Salivary arsenic as a biomarker for arsenic exposure. Cell Biol Toxicol 24:367-371
25. Lew K, Acker JP, Gabos S, Le XC (2010) Biomonitoring of arsenic in urine and saliva of children playing on playgrounds constructed from chromated copper arsenate-treated wood. Environ Sci Technol 44(10):3986-3991
26. Hall M, Chen Y, Ahsan H, Slavkovich V, van Geen A, Parvez F, Graziano J (2006) Blood arsenic as a biomarker of arsenic exposure: results from a prospective study. Toxicology 225(2-3):225-233
27. Le XC, Lu X, Ma M, Cullen WR, Aposhian HV, Zheng B (2000) Speciation of key arsenic metabolic intermediates in human urine. Anal Chem 72(21):5172-5177
28. Le XC, Ma M, Cullen WR, Aposhian HV, Lu X, Zheng B (2000) Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ Health Perspect 108(11):1015-1018
29. Del Razo LM, Styblo M, Cullen WR, Thomas DJ (2001) Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol 174(3):282-293
30. Raml R, Rumpler A, Goessler W, Vahter M, Li L, Ochi T, Francesconi KA (2007) Thio-dimethylarsinate is a common metabolite in urine samples from arsenic-exposed women in Bangladesh. Toxicol Appl Pharmacol 222(3):374-380
31. Mandal BK, Suzuki KT, Anzai K, Yamaguchi K, Sei Y (2008) A SEC-HPLC-ICP MS hyphenated technique for identification of sulfur-containing arsenic metabolites in biological samples. J Chromatogr B Anal Technol Biomed Life Sci 874(1-2):64-76
32. Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Vasken Aposhian H (2000) Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol 163(2):203-207
33. Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, Thomas DJ, Kligerman AD (2001) Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol 14(4):355-361
34. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Thomas DJ (2000) Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74(6):289-299
35. Charoensuk V, Gati WP, Weinfeld M, Le XC (2009) Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells. Toxicol Appl Pharmacol 239(1):64-70
36. Naranmandura H, Ogra Y, Iwata K, Lee J, Suzuki KT, Weinfeld M, Le XC (2009) Evidence for toxicity differences between inorganic arsenite and thioarsenicals in human bladder cancer cells. Toxicol Appl Pharmacol 238(2):133-140
37. Suzuki S, Arnold LL, Pennington KL, Chen B, Naranmandura H, Le XC, Cohen SM (2010) Dietary administration of sodium arsenite to rats: relations between dose and urinary concentrations of methylated and thio-metabolites and effects on the rat urinary bladder epithelium. Toxicol Appl Pharmacol 244(2):99-105
38. Naranmandura H, Bu N, Suzuki KT, Lou Y, Ogra Y (2010) Distribution and speciation of arsenic after intravenous administration of monomethylmonothioarsonic acid in rats. Chemosphere 81(2):206-213
39. Cullen WR, McBride BC, Manji H, Pickett AW, Reglinski J (1989) The metabolism of methylarsine oxide and sulfide. Appl Organometal Chem 3:71-78
40. Naranmandura H, Suzuki N, Iwata K, Hirano S, Suzuki KT (2007) Arsenic metabolism and thioarsenicals in hamsters and rats. Chem Res Toxicol 20(4):616-624
41. Challenger F (1945) Biological methylation. Chem Rev 36:315-361
42. Nigg HN, Stamper JH, Malory LL (1993) Quantification of human exposure to ethion using saliva. Chemosphere 26:897-906
43. Rafael G, Pascale B, Zul V, Paul H, Gideon K (1997) Is saliva suitable for therapeutic monitoring of anticonvulsants in children: an evaluation in the routine clinical setting. Ther Drug Monit 19:637-642
44. Denovan LA, Lu C, Hines CJ, Fenske RA (2000) Saliva biomonitoring of atrazine exposure among herbicide applicators. Int Arch Occup Environ Health 73(7):457-462
45. Barbosa F Jr, Tanus-Santos JE, Gerlach RF, Parsons PJ (2005) A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs. Environ Health Perspect 113(12):1669-1674
46. Kuroda K, Yoshida K, Yoshimura M, Endo Y, Wanibuchi H, Fukushima S, Endo G (2004) Microbial metabolite of dimethylarsinic acid is highly toxic and genotoxic. Toxicol Appl Pharmacol 198(3):345-353
47. Yoshida K, Kuroda K, Zhou X, Inoue Y, Date Y, Wanibuchi H, Fukushima S, Endo G (2003) Urinary sulfur-containing metabolite produced by intestinal bacteria following oral administration of dimethylarsinic acid to rats. Chem Res Toxicol 16(9):1124-1129
48. Kamoun P (2004) Endogenous production of hydrogen sulfide in mammals. Amino Acids 26(3):243-254
49. Suzuki KT, Iwata K, Naranmandura H, Suzuki N (2007) Metabolic differences between two dimethylthioarsenicals in rats. Toxicol Appl Pharmacol 218(2):166-173
50. Buchet JP, Lauwerys R, Roels H (1981) Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int Arch Occup Environ Health 48(2):111-118
51. Styblo M, Delnomdedieu M, Thomas DJ (1996) Mono- and dimethylation of arsenic in rat liver cytosol in vitro. Chem Biol Interact 99(1-3):147-164
52. Li J, Waters SB, Drobna Z, Devesa V, Styblo M, Thomas DJ (2005) Arsenic (+3 oxidation state) methyltransferase and the inorganic arsenic methylation phenotype. Toxicol Appl Pharmacol 204(2):164-169